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Purpose: Betanin is a betacyanin with antioxidant and anti-inflammatory activities whose effects were
investigated in a nonalcoholic steatohepatitis (NASH) model. Main methods: Ninety-six male naval medical
research institute (NMRI) mice were divided into eight groups (n5 12) including normal control, high fat diet
(HFD), Sham, and positive control treated with trans-chalcone. Three experimental groups were treated with 5
mg/kg, 10 mg/kg or 20 mg/kg betanin, and a betanin protective group was also defined. Results: Four weeks of
HFD treatment resulted in steatohepatitis with associated fibrosis. Significant increase was observed in serum
levels of triglycerides (TG), total cholesterol (TC), glucose, insulin, leptin, liver enzymes, malondialdehyde
(MDA), furthermore insulin resistance and (sterol regulatory element-binding protein-1c) SREBP-1c were
detected. Levels of high-density lipoprotein cholesterol (HDL-C), adiponectin, superoxide dismutase (SOD),
catalase (CAT), and PPAR-a (peroxisome proliferator-activated receptor-a) considerably decreased. Treat-
ment by betanin, particularly the 20 mg/kg dosage, attenuated these changes. Conclusion: Betanin is a potential
treating agent of steatohepatitis and works through up-regulation of PPAR-a, down-regulation of SREBP-1c,
modification of adipokine levels and modulation of lipid profile.pCorresponding author. Shodada Hesarak blvd, Daneshgah Square, Sattari Highway, Tehran, 1477893855, Iran.
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is a metabolic dysfunction that can progress to
nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis. In the progression of NAFLD
to NASH, various factors are involved such as triglyceride accumulation and oxidative stress [8].
Peroxisome proliferator activated receptors (PPARs) and sterol regulatory element-binding
proteins (SREBPs) are important in the pathogenesis of NAFLD/NASH as they play a role in
regulating fatty acid and cholesterol homeostasis via fatty acid oxidation and lipogenesis [21,
26]. In the liver, PPAR-a influences the genes related to fatty acid b-oxidation [36], inhibits the
expression of inflammatory genes, and increases the expression of antioxidant-related genes [4,
41]. SREBP-1c is regulated by PPAR-a agonists [26]. Overexpression of SREBP-1c leads to
accumulation of triglycerides (TG) in the liver to cause NAFLD [19].
Accordingly, antioxidants and free radical scavengers should possess therapeutic potential in
the treatment of NASH [1]. Beetroot juice is used as a traditional treatment for liver diseases and
for stimulation of the immune system [35]. Betanin (betanidin 5-O-b-D-glucoside) can be
considered a main active ingredient with a principal role in the effects of beetroot [11].
Betanin structure includes phenolic and cyclic amine groups, which are good electron do-
nors, and thus have a remarkable free-radical scavenging property. Antioxidant and anti-in-
flammatory properties of betanin [22], as well as inhibition of lipid peroxidation and the
oxidation of low-density lipoproteins (LDL) have been reported [15].
The aim of this study was to assess the effect SOF betanin on biochemical and histological
indicators, PPAR-a and SREBP-1c expression in NASH model.MATERIALS AND METHODS
Materials
All materials were purchased from Sigma-Aldrich (Sigma–Aldrich, St. Louis, MO, USA) unless
stated. Commercial kits were used for the evaluation of low-density lipoprotein cholesterol
(LDL-C), high-density lipoprotein cholesterol (HDL-C), very low density lipoprotein (VLDL),
TG, total cholesterol (TC), alanine aminotransferase (ALT), aspartate aminotransferase (AST),
alkaline aminotransferase (ALP), and glucose in serum and provided from ZistChimi Chemical
Company, Tehran, Iran. Serum leptin and adiponectin were measured with Mouse Leptin
ELISA Kit from Yanaihara Institute Inc., Japan, and Mouse adiponectin ELISA kit by Otsuka
Pharmaceutical Co., Japan respectively. Serum insulin assays were done with Mouse Ultrasen-
sitive Insulin ELISA kit (ALPCO Diagnostics, USA). EnzyChrom Phospholipid Assay Kit
(EPLP-100) (Belgium) was used for phospholipid assessment. The cytokine tumor necrosis
factor-alpha (TNF-a) level in serum was analyzed by Mouse TNF-alpha ELISA Kite Bioscience,
USA. High Pure RNA Isolation Kit (Roche, Switzerland) was used for RNA isolation and Revert
Aid First Strand cDNA Synthesis Kit (Thermo Scientific, USA) was used for cDNA synthesis.
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were obtained from YektaTajhizAzma, Iran.
Animals
Male naval medical research institute (NMRI) mice weighing 25 ± 5 g were purchased from the
Pasteur Institute, Karaj, Iran. All animals were kept in the same room under standard conditions
with a 12 h light/dark cycle at 22–24 8C and had ad libitum access to standard pellet and water.
Experimental protocol
Animals were weighed and divided into the eight following groups (n 5 12 in each group):
 Normal Control group: receiving a normal rodent diet (NC)
 High Fat Diet group: receiving a high fat regime (HFR) (details described below in 2.3.1 HFR)
for 4 weeks (HFD)
 Sham group: receiving a HFR for 4 weeks and shifted to a NC with betanin solvent (Distilled
water) by intra-peritoneum injection for 3 weeks
 Positive Control group: receiving a HFR for 4 weeks and shifted to a NC with trans-chalcone
(24 mg/kg body weight) [17] by intra-peritoneum injection for 3 weeks (PC)
 Experimental group I, II and III: receiving a HFR for 4 weeks and shifted to a NC with 5, 10
and 20 mg/kg doses of betanin respectively, by intra-peritoneum injection for 3 weeks (eB1,
eB2, and eB3)
Protective group: receiving a HFR alongside with high dose of betanin (20 mg/kg body
weight) administered by intra-peritoneum injection for 4 weeks (PB). A summary of the groups
can be found in Supplementary Table I.
High fat regime. NAFLD was induced by oral gavage (8 mL/kg/day) of a liquid emulsion,
(Supplementary Table II) and feeding simultaneously the animals with ad libitum HF diet
(supplementary Table III) that consists of 43.11% fats (1.12% cholesterol) and 0.18% fructose.
Treatment. Treatment was performed according to the experimental protocol for 3 weeks. The
experimental protocol was performed in accordance with the international guidelines estab-
lished in the Guide for the Care and Use of Laboratory Animals and further approved by the
University’s Internal Ethics committee (approval code: 176947).
Histological and biochemical assayBlood serum preparation and analysis. Animals were anesthetized by inhalation of diethyl
ether, after which a terminal blood sample was withdrawn from cardiac ventricles was per-
formed. Blood samples were allowed to clot for 60 min at room temperature and then centri-
fuged at 3000 rpm at 30 8C for 10 min to separate the serum. Insulin resistance index was
evaluated by the homeostasis model assessment (HOMA) formula: HOMA 5 fasting serum
insulin (mU/L) 3 fasting plasma glucose (mM)/22.5 [29]. The atherogenic index was calculated
as follows: Atherogenic Index (AI) 5 (TC-HDL-C)/HDL-C.
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diately fixed in a 10% formalin buffer solution for histopathological evaluation. Tissues were
embedded in paraffin and cross-sectioned into 5 mm sections according to routine protocols.
Liver sections were stained with hematoxylin & eosin (H&E) and Masson’s trichrome (MT). The
slides were examined by light microscopy.
Liver homogenate preparation for antioxidant enzymes and biochemical assays. Liver tissue
was also used for biochemical determination of catalase (CAT), superoxide dismutase (SOD),
malondialdehyde (MDA) activities and LDL-C, HDL-C, VLDL, phospholipid, TG, TC, total
lipid (TL) and total protein (TP) levels. First, tissue samples were frozen in liquid nitrogen until
biochemical analyses were performed. They were homogenized (1:3, w/v) in phosphate saline
buffer (pH 7.4). After homogenization, samples were sonicated for 1.5 min with bursts of 30 s.
All procedures were performed at 0–4 8C. Homogenate samples were centrifuged at 22,000 g for
17 min at 4 8C, in a microcentrifuge. The supernatant was frozen at 40 8C until the time of
assay. Levels of LDL-C, HDL-C, VLDL, phospholipid, TG, TC, TP, TL and activities of CAT,
SOD, MDA were determined using commercially available kits.
RNA analysis and cDNA preparation
Total RNA was extracted from liver tissues by High Pure RNA Isolation Kit protocol of Roche
(Switzerland). Purified RNA was stored at 80 8C for later analysis. cDNA synthesis was done
with Thermo Scientific kit protocol. Real-time quantitative PCR (qPCR) was performed by YTA
SYBR Green qPCR MasterMix 2X protocol (YektaTajhizAzma, Iran).
Primer sequences for SREBP-1c, PPAR-a and hypoxanthine guanine phosphoribosyl
transferase (HPRT) (used as a housekeeping gene) were obtained from the National Center for
Biotechnology Information (NCBI) website. Specific primers were designed by the Primer ex-
press program (shown in supplementary Table IV).STATISTICAL ANALYSIS
One-way ANOVA was used, and the results were expressed as the mean ± SEM (standard error
of the mean) followed by Tukey’s post hoc test (SPSS V.24, IBM Corporation, New York, USA).
The level of statistical significance was set at P < 0.05.RESULTS
Body weight
Initially, there was no body weight difference between groups. After four weeks, body weight
increase was less in the groups that received HFR vs. NC group. The NASH model group and
the protective group were sacrificed at this time (Table 1). Weight difference was significant in
HFD, Sham (P < 0.01) and PC (P < 0.05) groups vs. NC group. After removing HFR from mice
diet, significantly lower body weight was still observed in Sham, eB1 and eB2 groups vs. NC
group (P < 0.001), so that the NC group gained ∼1 g, Sham lost ∼1 g, eB1 and eB2 groups gained
0.62 g and 0.92 g, respectively, during the 3 weeks of drug treatment, whereas the PC and eB3
Table 1. Comparison of body weights
Groups NC HFD Sham PC eB1 eB2 eB3 PB
Start week(g) 25.91 ±
1.17








31.08 ± 0.65þþ 32.58 ± 2.30þ 32.25 ± 0.54þ 32.83 ± 0.69 33.12 ± 0.71 33.37 ±
0.64
Final week(g) 38.66 ±
0.80









Data are expressed as means ± SEM.
þP < 0.05, þþP < 0.01, þþþP < 0.001 vs. normal control group.
**P < 0.01, ***P < 0.001 vs. HFD group.







Table 2. Effects of betanin on serum biochemical parameters in HFR-fed mice
Groups NC HFD Sham PC eB1 eB2 eB3 PB
Parameters
TG (mg/dL) 71.14 ± 2.25 136.25 ±
2.85þþþ






79.47 ± 1.87***,### 87.49 ±
1.65þþþ, ***,###
































38.32 ± 3.38 126.55 ±
3.49þþþ












17.64 ± 0.30***,# 18.24 ±
0.39***,#
TP (mg/dL) 2.68 ± 0.12 4.30 ± 0.12þþþ 4.17 ± 0.16þþþ 2.60 ±
0.10***,###
4.58 ± 0.09þþþ 4.63 ± 0.07þþþ 4.02 ± 0.04þþþ 3.93 ± 0.15þþþ








0.74 ± 0.06 1.99 ± 0.18þþþ 1.31 ± 0.14þ,* – – – 1.40 ± 0.12þ,* 1.56 ± 0.14þþ





225.94 ± 4.58þþþ 129.33±2.92þ,***,### 154.74 ±
2.75þþþ,***,###
Data are expressed as means ± SEM.
þP < 0.05, þþP < 0.01, þþþP < 0.001 vs. normal control group.
*P < 0.05, **P < 0.01, ***P < 0.001 vs. HFD group.
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< 0.001), and eB2 (P < 0.01) groups showed significant higher body weight vs. Sham (Table 1).
Effect of betanin on biochemical parameters
TG, phospholipid, TL, LDL-C, and VLDL showed a significant increase in the HFD and Sham
groups vs. NC group (P < 0.001). On the other hand, these parameters were significantly
decreased in the treated groups, approaching normal values at the highest dose of betanin (TG
to 79.47 and VLDL to 17.64 mg/dl); the two lower doses of betanin also reduced these levels, but
to a lesser extent. HDL-C levels were markedly reduced in the HFD and Sham, but significantly
increased in the treated groups, especially in the eB3 and PB groups. TC levels were markedly
increased in the HFD and Sham, and significantly reduced in the treated groups except for eB1.
TP levels were markedly increased in the HFD and Sham, but reduced only in the PC group (to
2.6 mg/dl), and differences seen in the eB3 and PB groups were not significant. TP levels did not
show any decrease in the eB1 and eB2 groups. Fasting blood sugar (FBS), insulin levels and
insulin resistance were significantly increased in the HFD and Sham vs. NC group. These pa-
rameters were increased respectively in the HFD group and remained elevated in Sham. These
factors were markedly reduced in the eB3group (FBS to 99.67 mg/dl, insulin to 1.4 mg/dl, and
HOMA to 6.17 mg/dl) and the apparent decrease in PB group was not significant. Decrease of
insulin level and insulin resistance was more significant in Sham than in the HFD group. AI was
markedly increased in HFD and Sham vs. NC group and was decreased to ∼129 by high-doseFigure 1. Effects of betanin on the levels of liver enzymes (A: AST&ALT, B: ALP) in HFR-fed mice. Data
are expressed as the means ± SEM. þP < 0.05, þþP < 0.01, þþþP < 0.001 vs. normal control group. **P <
0.01, ***P < 0.001 vs. HFD group. #P < 0.05, ##P < 0.01, ###P < 0.001 vs. Sham group
Table 3. Effects of betanin on liver antioxidant enzymes in HFR-fed mice



























































Data are expressed as means ± SEM.
þþþP < 0.001 vs. normal control group.
*P < 0.05, **P < 0.01, ***P < 0.001 vs. HFD group.
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(P < 0.001) (Table 2).
Levels of AST, ALT and ALP were significantly increased in the HFD and Sham groups vs.
NC group (P < 0.001) (Fig. 1). Trans-chalcone restored AST and ALT levels to normal.
Treatment with betanin in both treatment and protective modes resulted in a significant
decrease in the amount of AST and ALT (except for the eB1 group) vs. HFD and Sham
(Fig. 1A). ALP levels did not show a significant decrease in treated groups (Fig. 1B). The levels of
SOD, CAT, MDA and ferric reducing ability of plasma (FRAP) were affected by HFR.
Compared with control, HFD and Sham, decreases were seen in SOD, CAT and FRAP (Table 3).
In comparison, the serum levels of SOD, CAT and FRAP showed a significant increase, whereas
MDA exhibited a significant reduction in PC and betanin-treated groups in a dose-dependent
manner (except for eB1 group) (Table 3). Serum leptin was found to increase considerably,
doubled in HFD and was elevated in Sham; it was significantly reduced by consumption of a
higher dose of betanin (20 mg/kg), but was ineffective in the protective mode (Fig. 2A). Serum
adiponectin levels were significantly reduced in the HFD and Sham and remarkably increased in
the PC and eB3 groups. This increase was not considerable in the other treated groups (Fig. 2B).
TNF-a was markedly enhanced in the HFD and Sham, but did not show a significant decrease in
the eB3 and PB groups vs. HFD and Sham (Fig. 2C).
Histopathological assessment
Liver tissue sections were stained with hematoxylin & eosin (Supplementary Fig. 1) and Mas-
son’s trichrome (Supplementary Fig. 2). Liver sections of the control group showed unre-
markable tissue with preserved architecture (Fig. S1A, Fig. S2A). Tissue steatosis (Fig. S1B, C)Figure 2. Effects of betanin on the serum levels of leptin (A), adiponectin (B) and TNF-a (C) in HFR-fed
mice. Data are expressed as the means ± SEM. þþþP < 0.001 vs. normal control group. ***P < 0.001 vs.
HFD group. ##P < 0.01, ###P < 0.001 vs. Sham group
Figure 3. Effects of betanin on the expression levels of PPAR-a and SREBP-1c in HFR-fed mice. Data are
expressed as the means ± SEM. þP < 0.05, þþP < 0.01, þþþP < 0.001 vs. normal control group. ***P < 0.001
vs. HFD group. ###P < 0.001 vs. Sham group
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HFD group sections showed moderate microvesicular and macrovesicular steatosis (score 3),
ballooning degeneration (score 3), Mallory-Denk bodies, accumulation of inflammatory cells
(score 3), moderate necroinflammatory activity (Fig. S1B, C) and moderate pericellular, peri-
vascular and bridging fibrosis (score 3) (Fig. S2 B, C). The Sham group showed mild micro-
vesicular and macrovesicular steatosis (score 1), ballooning degeneration (score 3) (Fig. S1D)
and pericellular and periportal fibrosis (score 2) (Fig. S2D). The treated groups showed normal
histology (Fig. S1E-I, Fig. S2 E–I). Liver sections of PC and eB1, eB2 and eB3 groups seemed
reversed to normal conditinon, but the PC group showed inflammation score 1 [18]. Liver
sections of PB improved moderatly.
PPAR-a and SREBP-1c mRNA expression level
PPAR-a and SREBP-1c expression levels showed a marked decrease and increase, respectively,
in the HFD and Sham groups in comparison with the NC group (P < 0.001), whereas treatment
with betanin improved their expression in the eB3 group with a significant difference from the
HFD and Sham groups (P < 0.001) (Fig. 3).DISCUSSION
Based on our results, some of the groups have shown a notable decrease in their body weight
compared with NC group. Due to the presence of some components in HFR such as sodium
deoxycholate, Tween 80 and propylene glycol, this diet did not cause a body weight gain in the
mice. Similarly, MCD (methionine and choline deficient) diet, which is used for preclinical
NASH studies, is shown to cause important weight loss [23]. Sodium deoxycholate is a bile salt
that is used as lipid and phospholipid solubilizer [31]. This component facilitates fat absorption
in the intestine. Tween 80 is used as a co-emulsifier for HFD emulsion [28]. Propylene glycol, as
an anti-ketosis agent, is able to collect blood FFAs that were released by sodium deoxycholate
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comparison with the NC group (Table 1). It seems that betanin is effective at a higher dose (20
mg/kg) in the normalization of body weight. This finding is consistent with previous reports
about betanin-rich djulis grains and beetroot crisps, in rats receiving dyslipidemic diets [38, 40].
In the current study, HFR intake caused an increase in the levels of TG, TC, phospholipids,
TL, LDL-C, and VLDL, whereas HDL-C was decreased. These changes are also observed in
NAFLD and NASH. HFR intake raised TP levels similar to the observations in a recent study
[6], but betanin was not effective in this case when administered at 5, 10 or 20 mg/kg for 3
weeks.
Our results showed that betanin remarkably increased HDL-C levels and significantly
lowered other lipid profile parameters. Trans-chalcone at 24 mg/kg decreased notably TG, TC,
VLDL, and TP levels. This compound is a precursor of flavonoids and exhibits antioxidant and
anti-inflammatory effects. According to a previous report, trans chalcone significantly reduced
the levels of TG and TC in cholesterol-fed NMRI mice at 12 and 24 mg/kg [17]. In another
study, trans-chalcone (12 mg/kg) did not decrease remarkably these parameters in obese mice
[16]. Previous studies have demonstrated that components containing betanin such as djulis and
red beet could reduce cholesterol, triglyceride and LDL levels and elevate levels of HDL [25, 38,
40]. Overall, betanin exerted beneficial anti-hyperlipidemic effects on the lipid profilein both
treatment and protection mode.
Insulin resistance is linked to the development of NASH and considered to be one of its
markers. It has a key role in the pathogenesis of NASH and is involved in hepatic lipid retention
[5]. Similarly to previous research, our results indicated that HFR consumption in mice leads to
a significant increase in FBS, insulin and HOMA index vs. normal group [5]. Our findings
showed a remarkable decrease in FBS, insulin, and HOMA values upon treatment with betanin.
Other studies have reported that administration of betacyanins to high-fat diet-fed mice and of
betanin to high-fructose-fed rats ameliorates glucose, insulin, insulin resistance, and obesity [14,
33]. Leptin is involved in insulin resistance that is increased by HFR consumption, whereas
betanin administration decreased leptin levels and, consequently, attenuated insulin resistance.
Based on these data, betanin showsan anti-insulin resistance effect. Since dyslipidemia and
oxidative stress enhance insulin resistance [37], it seems that the anti-insulin resistance effect is
related to the anti-hyperlipidemia and anti-oxidant effects of betanin. The anti-diabetic effects of
red beet have been demonstrated in previous reports [25]. In this regard, the highest dose of
betanin in the treated groups was more effective (compared with the protective mode).
In the current research, HFR significantly increased AI in HFD and Sham. High fat results in
oxidative stress, which increases LDL oxidation that is an important contributor to athero-
genesis. Antioxidants, including betalains, would thus counteract atherosclerosis [40]. Betanin
can reach the circulation and distribute in LDL and red blood cells, where the molecule is
presumably involved in antioxidant protection [22]. A previous study has shown that betanin
attenuates LDL oxidation [2]. Parallel with these findings, our study showed that betanin
remarkably decreased AI and improved antioxidant enzyme levels in our treated groups. In this
case, both treatment and protective modes were effective.
By administration of HFR, MDA was enhanced and SOD, CAT, and FRAP decreased
significantly. Oxidative stress is responsible for triggering ROS which is a risk factor in the
progression of hepatic diseases and lipid peroxidation within the cell, which ultimately results in
the formation of MDA [17]. Antioxidant enzymes such as SOD and CAT protect cells against
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expresssion of antioxidant enzymes by activation of the nuclear erythroid-2-related factor 2 [20].
Antioxidant, anti-radical and anti-inflammatory effects of betanin have been described in
previous studies. Betanin is also able to inhibit lipid peroxidation through inhibition of nitrogen
dioxide and lipoperoxyl radical-scavenging activity [2]. In the present study, betanin attenuated
oxidative stress caused by HFR, displaying decreased MDA and increased SOD and CAT and
FRAP levels. These results indicate betanin’s protective effect, which parallels previous reports
about betalains exhibiting free radical scavenging and antioxidant activities [7, 15].
Serum AST, ALT, and ALP levels are elevated in NASH [12]. In the current study, HFD and
Sham showed an increase in the plasma levels of these parameters, whereas betanin treatment
reduced AST and ALT, in accordance with previous studies [7, 15]. In this regard too, the
compound may act by influencing antioxidant defenses. ALP levels did not show a significant
decrease in treated groups. In previous studies, administration of red pitaya juice supplemen-
tation to high-carbohydrate, high-fat diet-fed fed rats and of table beet powder to rats with fatty
liver decreased ALP levels [30, 32]. It seems that a higher dose of betanin is more effective. In
this research, trans-chalcone decreased AST, ALT, and MDA levels and increased FRAP
significantly.
Adipokines have a role in the pathogenesis of NASH, where lower adiponectin levels are
correlated with the severity of the disease, through their metabolic and pro-/anti-inflammatory
activity. According to our results, like in other previous studies, HFR caused a notable reduction
of adiponectin and increase of leptin and TNF-a levels [39]. At the highest dose used, betanin
significantly increased adiponectin and decreased leptin, and was more effective in the treated
groups compared with the protective mode. Also, trans-chalcone markedly increased adipo-
nectin in comparison with HFD and Sham. This result is in parallel with a study on trans-
chalcone at 12 and 24 mg/kg doses [17]. Haizhao Song et al. have reported betacyanins of pitaya
peel to increase the level of adiponectin and the hepatic expression of its receptor, AdipoR2
(adiponectin receptor 2) [33]. Adiponectin improves the regulation of fatty acid and glucose
metabolism, and AdipoR2 activates the PPAR-a ligand as well as fatty acid oxidation and
glucose uptake by adiponectin [39].
Our results did not show a significant effect for betanin on TNF-a at either dose. Another
study on an acute lung injury model has shown a decrease in TNF-a levels by doses of 25 and
100 mg/kg betanin [13]. According to other data, pro-inflammatory cytokines such as TNF-a
were decreased by beet root ethanolic extract in gentamicin-induced nephrotoxicity of rodent
model, by betalain-rich oral capsules made from beetroot extracts in osteoarthritic patients, and
also by betalain in edema models [9, 24, 27].
The PPAR-a gene plays a crucial role in the balance of lipids and glucose, and its expression
is remarkably reduced in NAFLD and NASH. PPAR-a agonists have been suggested to act
against NASH [34]. Overexpression of SREBP-1c can lead to NAFLD/NASH (19). Inhibition of
SREBP can treat diseases associated with abnormal lipid metabolism, such as NASH [42].
mRNA and protein levels of SREBP-1c are mainly regulated by insulin [10]. HFR was shown
here to down-regulate PPAR-a and up-regulate SREBP-1c, whereas betanin treatment corrected
these effects to some extent. Betanin may act by antioxidant activity and by modifying insulin
and lipid profiles.
Based on our histological analysis of liver, HFR markedly induced lipid accumulation by
hepatocytes and caused inflammation and NASH with fibrosis, whereas lipid accumulation,
Physiology International 107 (2020) 1, 67–81 79inflammation and fibrosis were alleviated by betanin. Haizhao Song et al.’s findings concerning
the effects of betacyanins were in accordance with our results [33]. In the current study, steatosis
and hepatocyte ballooning were markedly decreased after treatment with betanin. These findings
suggest that betadin, in a dose-dependent way, helped the restoration of hepatocytes by
improving the activity of antioxidant enzymes and the lipid profile, ameliorating adiponectin
and leptin levels, and by up-regulating PPAR-a and down-regulating SREBP-1c.
CONCLUSION
In conclusion, betanin has antioxidant, anti-insulin resistance and anti-hyperlipidemic effects
and could alleviate steatohepatitis. The effect is exerted through down-regulation of SREBP-1c,
up-regulation of PPAR-a in liver tissue, increases in antioxidant enzyme levels, leptin reduction,
adiponectin enhancement, lowering insulin resistance, and modulation of lipid profiles. We
suggest that betanin could be considered as a potential therapeutic agent for NAFLD/NASH.
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